The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Intravesical sacituzumab tirumotecan in participants with intermediate-risk non–muscle-invasive bladder cancer: The phase 1/2 TroFuse-027 study.
 
Joshua Meeks
Honoraria - Astellas Pharma; AstraZeneca; bristol meyers; CG Oncology; ferring; ImmunityBio; Imvax; Janssen; Merck; Pfizer; Photocure; Prokarium; Protara Therapeutics; Urogen pharma
Patents, Royalties, Other Intellectual Property - NMIBC genetic classifier (Inst); TCGA Classifier (Inst)
Other Relationship - Olympus
 
Roger Li
Stock and Other Ownership Interests - Beam Therapeutics; CRISPR therapeutics; Editas Medicine; Guardant Health; Intellia Therapeutics; Lilly
Honoraria - IBCG; MashupMD; UroToday
Consulting or Advisory Role - Bristol-Myers Squibb; CG Oncology; IconOVir Bio; ImmunityBio; Johnson & Johnson/Janssen; Lucence Diagnostics; Merck; Pfizer; Thericon
Research Funding - CG Oncology; Predicine; Valar Labs
Travel, Accommodations, Expenses - CG Oncology; Predicine
Other Relationship - Predicine
 
Ashish Kamat
Consulting or Advisory Role - Arquer Diagnostics; Asieris Pharmaceuticals; Aspira Women's Health (I); Astellas Pharma; AstraZeneca; CG Oncology; Cystotech; enGene; Ferring; Genentech; GlaxoSmithKline (I); ImmunityBio; Imvax; Janssen; Merck; Nonagen Bioscience; Pfizer; Seagen; Theralase; Valar Labs; Vivet Therapeutics
Research Funding - Arquer Diagnostics (Inst); enGene (Inst); FKD Therapies (Inst); Patient-Centered Outcomes Research Institute (PCORI) (Inst); Photocure (Inst); Seagen (Inst); SWOG (Inst)
Patents, Royalties, Other Intellectual Property - Patent: CyPRIT (Cytokine Predictors of Response to Intravesical Therapy) joint with UT MD Anderson Cancer Center
Other Relationship - Bladder Cancer Advocacy Network; European Urology Oncology; International Bladder Cancer Group (IBCG); Journal of Urology; UroToday
 
Girish Kulkarni
Honoraria - Abbvie; AstraZeneca Canada; Bayer; Knight Pharmaceuticals; Photocure; Tersera
Consulting or Advisory Role - Bristol-Myers Squibb; EMD Serono; enGene; Ferring; Janssen Oncology; Merck; Novartis; Pfizer; Theralase; Verity Pharmaceuticals
Research Funding - Johnson & Johnson/Janssen (Inst)
Travel, Accommodations, Expenses - Ferring
 
Noah Hahn
Honoraria - Medscape
Consulting or Advisory Role - AstraZeneca; ImmunityBio; Incyte; Janssen; Merck; Mirati Therapeutics; Natera; Pfizer; Pfizer/EMD Serono; Protara Therapeutics; Seattle Genetics/Astellas; Trya Biosciences; Verity Pharmaceuticals
Research Funding - Astex Pharmaceuticals (Inst); AstraZeneca/MedImmune (Inst); Bristol-Myers Squibb (Inst); Daiichi Sankyo/Astra Zeneca (Inst); Daiichi Sankyo/Astra Zeneca (Inst); EMD Serono/Merck (Inst); Genentech/Roche (Inst); HTG Molecular Diagnostics (Inst); Ikena Oncology (Inst); Incyte (Inst); Inovio Pharmaceuticals (Inst); Merck (Inst); Merck (Inst); Merck (Inst); Pieris Pharmaceuticals (Inst); Seattle Genetics/Astellas (Inst)
 
Ekta Kapadia
Employment - Merck
Stock and Other Ownership Interests - Merck
 
Qing Zhao
Employment - Merck
Stock and Other Ownership Interests - Merck
 
Hema Dave
Employment - Merck
Stock and Other Ownership Interests - Merck
 
Max Kates
Honoraria - American Urological Association; BCAN; Kaplan; MedStar Health; Urology Times